I see a bid for $2bill coming any day there is so much in the works for this company. First the BIOSIM of COPAXONE received FDA approval and now they are awaiting Humira BIOSIM decision a $12 bill/year plus along with Pancreatic Cancer drug that is fast tracked and Orphaned. A lot of moving parts 50 mi shares $200 mil cash and NO debt. BIG target in the pharma space seeking a DOUBLE from these levels
Would have been a great long term play on its own but won't be around for long!
TODAY i BOUGHT 2400 more MNTA and I feel it is going to be visited very soon. I think ENDP would be very wise in making a play for MNTA
MNTA is starting its slow and steady march, I could see ENDP as a Suitor buying them for a quick double to get it done!
Forgot to mention Humira another BIOSIM in development with BAXTER, drug had sales of $9 billion and there would be NO competition because the drug is extremely difficult to manufacture. That is what makes this space so attractive!!
There is a lot in the works with COPAXONE the big BioSIM coming to market in Sept and their Pancreatic Drug candidate moving towards fast track designation. The co has $190mm in cash NO debt and will be gobbled up any day now.
ENDO could break into the BIOSIM space with a fully functioning company that has full manufacturing capabilities and expertise and partnerships with Sandoz overseas. THIS could be gigantic for ENDP and the Cancer drug for the Pancreas could be multi billion with multiple apps for additional cancers
The latest eye treatment is showing big promise and Auxilum was slated to buy QLTI but then ENDP bought AUXL. I heard the sale will not be consumated? That is the rumor, check out the options with the 5 calls.